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Equine infectious anemia virus (EIAV) activates transcription via a Tat protein, a TAR element, and the equine elongation
factor positive transcription elongation factor b (P-TEFb). In human cells, EIAV Tat (eTat) can inhibit the ability of human
immunodeficiency virus type 1 (HIV-1) Tat (hTat) to activate transcription from the HIV-1 long terminal repeat, demonstrating
that EIAV Tat can interact nonproductively with human P-TEFb. To study the mechanism of EIAV Tat and HIV-1 Tat activation,
we developed an in vitro elongation assay that recapitulates EIAV Tat-mediated inhibition of HIV-1 Tat trans-activation. We
found that eTat specifically inhibits activation of elongation by HIV-1 Tat while having no effect on basal transcription
elongation. The competitive inhibition of hTat activation was reversed by an activity present in HeLa cell nuclear extracts,
most likely a form of P-TEFb. Recombinant P-TEFb (cyclin T1 and CDK9) overcame the inhibition of transcription by eTat but
in a nonspecific manner. EIAV Tat affinity chromatography was used to purify the activity present in nuclear extract that was
capable of reversing eTat inhibition. We characterized the protein components of this activity, which include cyclin T1, CDK9,
Tat-SF1, and at least three unidentified proteins. These data suggest that additional factors are involved in the mechanism
of Tat activation. © 2000 Academic Press
INTRODUCTION
The study of the regulation of transcription in complex
retroviruses has provided important insights into the
mechanisms of transcription control operative in eu-
karyotes (Cullen, 1992; Jones and Peterlin, 1994). Human
immunodeficiency virus type 1 (HIV-1) regulates its gene
expression through the interplay of specific DNA cis-
elements located within the long terminal repeat (LTR),
the TAR RNA element, the viral Tat protein (hTat). and
cellular factors (Jones and Peterlin, 1994). hTat activates
viral gene expression by enhancing the elongation effi-
ciency of RNA polymerase II (RNAP II) complexes
(Cullen, 1992). This process is mediated by the interac-
tion of hTat with a complex called positive transcription
elongation factor b (P-TEFb) (Cullen, 1998; Jones, 1997).
P-TEFb is minimally composed of the CDK9 kinase and
cyclin T1 and enhances RNAP II elongation efficiency,
presumably by phosphorylating the carboxyl-terminal do-
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356main (CTD) of the largest subunit of RNAP II (Cullen,
1998; Jones, 1997). hTat binds directly to cyclin T1, and
this complex is sufficient for TAR recognition (Wei et al.,
1998). Based on these and other findings, it has been
proposed that hTat activates viral transcription by recruit-
ing P-TEFb to RNAP II complexes transcribing the HIV-1
genome (Cullen, 1998; Jones, 1997).
The related lentivirus, equine infectious anemia vi-
rus (EIAV), regulates its transcription via similar mech-
anisms (Jones and Peterlin, 1994; Maury, 1998). Acti-
vation of the EIAV promoter requires expression of the
viral trans-activator EIAV Tat (eTat), which increases
viral transcription. Overall, hTat and eTat primary se-
quences are highly divergent; however, they have a
number of common features (Cullen, 1992). First, the
activation domains of both Tat proteins contain a con-
served core region that is functionally interchangeable
in transient transfection experiments (Carroll et al.,
1991; Derse et al., 1991; Dorn et al., 1990). Second,
both Tat proteins bind to their respective TAR elements
located at the 59 ends of the lentiviral mRNAs (Cullen,
1992). Third, hTat and eTat require P-TEFb to activate
transcription (Bieniasz et al., 1999).
Despite the aforementioned similarities, there are fea-
tures that differentiate Tat activation in these two lentivi-
ruses. For example, hTat and eTat bind to dissimilar TAR
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N OFRNA elements (Cullen, 1992). In addition, the ability of
hTat and eTat to activate transcription is species re-
stricted: eTat is active in equine and canine cells but not
in human and murine cells, whereas hTat is active in
human and canine but not in murine cells. Indeed, se-
quence differences in cyclin T1 orthologs have been
shown to account for the species restriction of Tat acti-
vation (Bieniasz et al., 1998, 1999; Fujinaga et al., 1999;
Garber et al., 1998; Wei et al., 1998; Albrecht et al., 2000).
n transient transfections in human cells, eTat inhibits
Tat activity, suggesting that eTat can interact with hcy-
lin T1, although nonproductively (Madore and Cullen,
993). These and other studies indicate that a step other
han cyclin T1 binding is responsible for the species
estriction of the Tat proteins (i.e., TAR recognition by the
at–cyclinT1 complex; Bieniasz et al., 1999; Bieniasz et
l., 1998; Madore and Cullen, 1993).
We developed a quantitative in vitro transcription
longation assay that mediates HIV-1 Tat activation,
nd we used this system to study the mechanism of
at activation. We found that eTat specifically inhibits
ctivation of elongation by hTat from the HIV-1 LTR
hile having no effect on the basal level of transcript
longation. We then used eTat as a competitive inhib-
tor to characterize the ability of recombinant P-TEFb
o reverse eTat inhibition. Recombinant P-TEFb over-
ame eTat inhibition but also had the nonspecific
ffect of increasing hTat-independent elongation. We
lso found that an activity present in HeLa cell nuclear
xtract could reverse eTat inhibition of hTat activation
n a specific manner, with no effect on basal transcrip-
ion. We then used eTat affinity chromatography of
uclear extract to purify the activity capable of revers-
ng eTat inhibition. The protein components of this
ctivity include cyclin T1, CDK9, Tat-SF1, and several
nidentified proteins. These data confirm the role of
-TEFb in eTat activation but also suggest that addi-
ional protein factors are involved in this process.
RESULTS
IAV Tat specifically inhibits HIV-1 Tat activation of
longation from the HIV-1 promoter
Previous work has shown that eTat inhibits the activity
f hTat in vivo (see Introduction). This inhibition is prob-
ably due to competitive binding of eTat to the P-TEFb
complex, forming an eTat–P-TEFb complex that is inca-
pable of binding to the HIV-1 TAR. We sought to repro-
duce this effect in vitro and to establish an assay that
would allow us to biochemically dissect the inhibition of
hTat activity by eTat. Transcription activation of the HIV-1
LTR by hTat can be reproduced in vitro by using HeLa
cell nuclear extracts (Marciniak et al., 1990a). In this
system, exogenous hTat specifically activated the HIV-1
eTat INHIBITIOpromoter but had no effect on the activity from the ade-
novirus major late promoter (Sune and Garcia-Blanco,
a
(1995). This activation was dependent on a functional TAR
element; hTat was unable to activate an HIV-1 promoter
containing critical mutations in the bulge sequence of
this element (Fig. 1A).
We performed experiments to test the ability of wild-
type and mutant eTat proteins to inhibit activation of the
HIV-1 promoter by hTat in vitro. Wild-type eTat protein
inhibited hTat-activated transcription from the HIV-1 pro-
moter (Fig. 1A). This inhibition was observed in a dose-
dependent manner (Fig. 1B). A 14-fold molar excess of
eTat practically abolished hTat activity, whereas the
same amount of R43G mutant eTat protein (mt) did not
affect hTat trans-activation (Figs. 1A and 1B). R43G is an
eTat mutant that is incapable of activating EIAV transcrip-
tion (Madore and Cullen, 1993). Basal transcription (i.e.,
hTat-independent transcription) from the HIV-1 promoter
was not significantly effected by eTat (Fig. 1A). These
results confirm previous in vivo data and provide further
vidence that the inhibition is the result of the seques-
ration of a common cellular factor.
To directly measure the elongation efficiencies of
ranscribing polymerases, we established an in vitro
Tat-dependent elongation assay that uses an HIV-1
TR double G-less cassette template. This template
ynthesizes transcripts that contain two regions (cas-
ettes) of different sizes that lack guanosine residues;
herefore, these G-less cassettes are resistant to di-
estion with RNaseT1. One G-less cassette is located
roximal to the promoter so as to measure the num-
ers of transcription complexes that reached nucleo-
ide 1183 (short), and the second, downstream, G-less
assette measures the number of transcripts beyond
ucleotide 11960 (long) (see Fig. 1C). The method for
uantifying elongation efficiency is described under
aterials and Methods.
In the elongation assay, exogenous hTat strongly in-
reased the level of long transcripts with minimal effect
n the level of short transcripts (Fig. 1D, lanes 1 and 2).
he hTat activation of long transcripts is reflected by
he increase in the elongation efficiency of RNAP II
omplexes formed on the HIV-1 promoter (Fig. 1F). The
ddition of eTat to these transcription reactions had a
inimal effect on the basal level of elongation by RNAP
I (Fig. 1D, lanes 3 and 5; see also Fig. 1F). However,
Tat dramatically reduced the levels of hTat-dependent
longation as observed by the decrease in the amount
f long transcripts (Figs. 1D, lanes 4 and 6, and 1E; see
lso Fig. 1F). The level of promoter proximal short
ranscripts remained unaffected by eTat (Fig. 1D, lanes 4
nd 6). Figure 1E shows the quantification of the data
n Fig. 1D in terms of trans-activation of long and short
ranscripts (as described under Materials and Methods).
hese results show that eTat can specifically inhibit
Tat-dependent activation of long transcripts while not
357hTat ACTIVITYffecting the levels of promoter proximal short transcripts
Fig. 1E). Figure 1F shows the elongation efficiencies
ting ba
re calc
˜ ´for transcription reactions where EIAV Tat was titrated in
FIG. 1. Inhibition of hTat transcription activity by eTat. (A) Transcriptio
or mutant (mt) eTat proteins and with hTat where indicated. Positions o
hTat activity by eTat is dose dependent. Transcription reactions were p
are indicated on top of the graph bars. Quantification of the experime
Materials and Methods. (C) Schematic representation of the HIV-1 LTR
(D) Inhibition of hTat-dependent activation of transcription elongation b
cassette and 3.5- and 7-fold molar excess of eTat protein in the absence
and the migration of long and short transcripts is indicated by arrows. (
from the experiment shown in panel D were quantified with a Phosphor
as explained under Materials and Methods, is shown graphically. (F)
specifically inhibits hTat-activated elongation efficiency while not affec
indicated at the bottom of the graph. Molar elongation efficiencies we
358 SUNthe absence or presence of hTat. The elongation efficien-
cies were measured using the HIV-LTR double G-lesscassette assay. These data clearly demonstrate the spe-
tions were carried out in the absence or presence of a wild-type (WT)
nd BL HIV-1 runoff products are indicated on the right. (B) Inhibition of
ed with increasing amounts of WT and mt R43G eTat proteins, which
ta is shown in graphic form and was calculated as described under
e G-less cassette template used in the experiment shown in panel D.
in vitro. Transcription reactions were carried out with a double G-less
presence (1) of hTat. RNA products were resolved by electrophoresis,
Tat inhibits hTat trans-activation of long transcripts. Experimental data
. The fold trans-activation of long and short RNA transcripts, calculated
n of eTat into transcription elongation assays demonstrates that eTat
sal elongation. The amount of eTat and hTat added to the reactions is
ulated as described under Materials and Methods.
AL.n reac
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erform
ntal da
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(2) or
E) EIAV
Imager
Titratio
E ETcific effect of eTat on hTat-activated elongation efficiency
(Fig. 1F).
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the order of addition
The results shown above are consistent with the se-
questration of the critical hTat cofactor or cofactors by
eTat (most likely hcyclin T1). One prediction of this sug-
gestion is that the association of hTat with this essential
cofactor before the addition of eTat would prevent inhi-
bition. We sought to test this hypothesis using the in vitro
transcription system. Exogenous eTat protein was added
to the transcription reaction before, after, or at the same
time as hTat, and the effects on HIV-1 transcription were
analyzed. The addition of eTat before or at the same time
as hTat inhibited activation of the HIV-1 LTR (Fig. 2A,
FIG. 2. Effect of the order of addition in the inhibition of hTat activity
by eTat. (A) Transcription reactions were carried out in the absence (2)
or presence (1) of hTat and/or eTat. Order and time of addition are
indicated on top of the figure. (A) Schematic representation of the
experiment is described below the figure. Positions of WT and BL HIV-1
runoff products are indicated on the right. (B) Experimental data, quan-
tified with the PhosphorImager, from the experiment shown in panel A.
Fold trans-activation was calculated as described under Materials and
Methods.
eTat INHIBITIOlanes 5 and 7); however, preincubation of hTat with
nuclear extract before eTat addition prevented the inhi-
R
(bition effect of the latter (Fig. 2A, lane 6). Quantification of
these data is shown in graph form in Fig. 2B. Several
conclusions can be drawn from these results. First, hTat
interacted with the elongation factor independently of the
TAR element (note that there was no ongoing transcrip-
tion during preincubation times). Second, the interaction
of hTat with the elongation factor was stable and did not
dissociate on the addition of a molar excess of eTat
competitor.
Heat-treated nuclear extract reverses EIAV Tat
inhibition of hTat activity
If the inhibition of hTat activity was due to the interac-
tion of eTat with a cellular factor (i.e., hcyclin T1), the
addition of nuclear extract to the transcription reactions
should reverse eTat inhibition of hTat activation. HeLa
nuclear extract was heat treated to inactivate the TATA-
binding protein (TBP) using the conditions described by
Nakajima et al. (1988). This heat-treated nuclear extract
(HTNE) is incapable of supporting transcription (Fig. 3A)
(Sune and Garcia-Blanco, 1995), does not affect Tat
trans-activation when added to HeLa nuclear extract
(Sune and Garcia-Blanco, 1995), and serves as a crude
source of Tat cofactors.
The addition of HTNE rescued hTat activity without
affecting the basal level of transcription (Fig. 3B). Quan-
tification of the long transcripts shows that HTNE spe-
cifically increased activation of long transcripts by hTat
(Fig. 3C). Measurement of the elongation efficiencies for
each reaction demonstrated that HTNE rescued hTat-
dependent activation of elongation but had no effect on
the basal level of elongation (Fig. 3D).
These data demonstrate that inhibition of the hTat
activity by eTat was reversible by cellular cofactors
present in nuclear extract. In particular, it is important to
note that the HTNE specifically reversed eTat inhibition
of hTat activation only, while having no effect on basal
transcription from the HIV-1 LTR. This result mirrors the
specificity of the eTat inhibition effect. These results
suggest that the HTNE supplies the critical hTat cofactor
activity that was sequestered by the eTat, which is most
likely a form of P-TEFb. Therefore, it would be reasonable
to conclude that addition of purified P-TEFb should yield
a similar result.
Purified recombinant P-TEFb can overcome eTat
inhibition but also nonspecifically increases basal
transcription
The hcyclin T1 and hCDK9 were coexpressed using a
recombinant baculovirus system (Peng et al., 1998). The
verexpressed proteins, herein referred to as recombi-
ant P-TEFb, were purified to near homogeneity (Fig. 4A)
nd shown to be active in stimulating elongation of
359hTat ACTIVITYNAP II transcribing an adenovirus major late promoter
AdMLP) double G-less cassette (Fig. 4B). We tested
basal
re calc
˜ ´whether recombinant P-TEFb could reverse eTat inhibi-
tion of hTat activity using the HIV-1 LTR double G-less
FIG. 3. Addition of nuclear extract overcomes inhibition of hTat acti
nuclear extract. Transcription elongation reactions were performed in t
control nuclear extract. Lanes 3 and 4 were performed with HTNE. Po
(B) HTNE reversed eTat inhibition of elongation when added to reactio
presence (1) of hTat. EIAV Tat (eTat) was present (1) in reactions in la
ml was added to reactions in lanes 7 and 8. (C) Quantification of long t
eTat inhibition of hTat activation of long transcripts while not affecting
elongation. Molar elongation efficiencies for experiment in panel B we
360 SUNcassette assay (Fig. 4C). The measured elongation effi-
ciencies for this experiment are shown in Fig. 4D. Re-combinant P-TEFb overcame the inhibition of hTat activity
(Fig. 4C, lane 6). However, unexpectedly recombinant
eTat. (A) Heat treatment inactivates the transcription activity of HeLa
ence (2) or presence (1) of hTat. Lanes 1 and 2 were performed with
of long and short transcripts are indicated by the arrows on the right.
nscription elongation reactions were performed in the absence (2) or
to 8. HTNE (3 ml) was added to reactions in lanes 5 and 6, whereas 6
pts from the experiment shown in panel B shows that HTNE reversed
transcription. (D) HTNE reversed eTat inhibition of hTat activation of
ulated as described under Materials and Methods.
AL.vity by
he abs
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nes 3
ranscri
E ETP-TEFb also dramatically increased the level of transcrip-
tion elongation from the HIV-1 LTR in the absence of hTat
PFIG. 4. Purified recombinant P-TEFb overcame eTat inhibition but also increases basal transcription. (A) Silver stain analysis of purified recombinant
P-TEFb. The full-length cyclin T1 and CDK9 subunits are indicated. (B) Recombinant P-TEFb is active in stimulating elongation by RNAP II on an
adenovirus major late promoter double G-less cassette template. Lane 1 contained no recombinant P-TEFb. Lanes 2–4 contained 1, 4, and 7 ml of
-TEFb, respectively. Lanes 5–7 contained 1, 4, and 7 ml of heat-inactivated P-TEFb (h.i. P-TEFb) (i.e., boiled for 5 min), respectively, as a control. (C)
Addition of recombinant P-TEFb to transcription reactions inhibited with eTat inhibition. Reactions were carried out using the HIV-1 LTR double G-less
cassette template. Lanes 1 and 2 are control reactions demonstrating efficient activation by addition of hTat (500ng). Lanes 3 and 4 show inhibition
of hTat activation but not basal transcription by the addition of a threefold molar excess of eTat. Lanes 5 and 6 show that the addition of P-TEFb (7
ml) increased elongation efficiency of both basal and hTat-activated transcription, respectively, in the presence of eTat. (D) Molar elongation
efficiencies for the experiment in panel C.
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˜ E´ ET(Fig. 4C, lane 5). This suggested that the recombinant
P-TEFb was in some way different from the activity
present in HTNE. It is important to emphasize again that
the latter only reversed the eTat effect in the presence of
hTat while not affecting basal transcription (Fig. 3). These
results also suggest that the recombinant P-TEFb is
capable of bypassing the hTat regulatory mechanism. It
should be noted that the levels of P-TEFb, as determined
using immunoblot assays, were similar in the recombi-
nant P-TEFb and the HTNE (data not shown). Also, the
effect of P-TEFb on both basal and hTat-activated tran-
scription was dose dependent (data not shown). In ad-
dition, we observe that the addition of P-TEFb to standard
in vitro transcription reactions using the HIV-1 LTR tem-
late results in an increase in both basal and hTat-
ctivated transcription (data not shown). The simplest
nterpretation of these findings, which is consistent with
esults of others, is that the recombinant P-TEFb is miss-
ng a regulatory component or components. These fac-
ors, we conjecture, would make P-TEFb highly depen-
ent on recruitment by Tat.
urification of EIAV Tat binding proteins and an
ctivity capable of overcoming EIAV Tat inhibition
We next sought to characterize the proteins with which
Tat interacts to further characterize the mechanism by
hich it inhibits hTat activity. For this purpose, we con-
tructed affinity columns with wild-type eTat or the non-
unctional R43G mutant eTat protein (see Materials and
ethods). Nuclear extracts were loaded onto these af-
inity columns, and after extensive washing, the retained
roteins were eluted with identical salt gradients. Chro-
atographic fractions from each column were subse-
uently analyzed for activity and protein composition.
liquots of the gradient fractions from wild-type and
utant eTat columns were tested in the in vitro elonga-
tion assay in the presence of hTat and eTat. An activity
capable of overcoming eTat inhibition was observed in
fractions obtained from a wild-type eTat column (Fig. 5A)
but not from the mutant eTat column (data not shown).
The measured elongation efficiencies for this experiment
are shown in Fig. 5B. In another experiment, we tested
fractions eluted from a wild-type eTat affinity matrix for
the ability to overcome eTat inhibition in the absence or
presence of hTat. We did not observe an effect of the
fractions on basal transcription (data not shown).
To characterize the factors that specifically bound
wild-type eTat columns but not mutant eTat columns, we
analyzed the proteins present in each fraction in parallel.
The proteins present in the gradient fractions from wild-
type and mutant eTat affinity columns were separated by
SDS–PAGE and subjected to immunoblot analysis. The
P-TEFb subunits cyclin T1 and CDK9 were present in the
362 SUNactive fractions from the wild-type column (Fig. 5C). Bind-
ing of these proteins to the eTat matrices was specific,because we could not detect binding of other nuclear
proteins like PCNA (Fig. 5C) and binding was observed
only for the wild-type eTat column. These results also
provide an explanation for why the R43G mutant eTat
cannot activate EIAV transcription and why it does not
inhibit hTat; it is incapable of binding to cyclin T1.
In addition to P-TEFb, TFIIF, TFIIH, Sp1, Tat-SF1, and
CA150 have been implicated in the mechanism of hTat
activation (Cujec et al., 1997; Jeang et al., 1993; Kato et
al., 1992; Sune and Garcia-Blanco, 1999; Sune et al.,
1997; Zhou and Sharp, 1996). We sought to investigate
the presence of these proteins in the gradient fractions
from wild-type and mutant eTat columns. Tat-SF1, an
elongation factor implicated in the mechanism of hTat
activation (Zhou and Sharp, 1996; Li and Green, 1998),
coeluted with the activity capable of overcoming eTat
inhibition from the wild-type eTat column and was not
present in mutant eTat fractions (Fig. 5C). This may
indicate a role for this protein in the reversal of eTat
inhibition. Sp1 was not detected in the fractions (data not
shown). CA150, another elongation factor implicated in
hTat activation (Sune and Garcia-Blanco, 1999; Sune et
al., 1997), bound to both columns but eluted from the
wild-type column at a higher salt concentration than from
the mutant column (data not shown). TFIIH and TFIIF
components bound to both columns without apparent
specificity (data not shown).
To further analyze the composition of eTat chromato-
graphic fractions, we performed silver stain analysis and
compared the proteins eluted from both columns. Pro-
teins with the same relative mobility as hcyclin T1 (87
kDa) and CDK9 (42 kDa) were identified in the active
fractions from the wild-type eTat column (Fig. 5D). Impor-
tantly, other proteins that specifically eluted from the
wild-type column with an elution pattern similar to hcy-
clin T1 were also identified in the active fractions
(marked in Fig. 5D). These proteins had approximate
molecular masses of 140, 32, and 15 kDa. Tat-SF1 mi-
grates on SDS–PAGE at about 140 kDa, so it was possi-
ble that the 140-kDa protein detected in the silver stain
was Tat-SF1. Additional chromatography and Western
blotting, however, demonstrated that the major 140-kDa
protein detected in the silver stain was not Tat-SF1 (data
not shown). The 140-, 32-, and 15-kDa proteins may be
important components of a P-TEFb complex that is bound
and functionally sequestered by eTat. Future work to
purify, sequence, and clone these proteins may provide
valuable insight into the mechanism of Tat function.
DISCUSSION
Overexpression of eTat had been shown to inhibit
hTat-dependent transcription activation of the HIV-1 LTR
in vivo (Madore and Cullen, 1993). In this report, we
AL.describe an in vitro transcription elongation system de-
veloped to study the mechanism of Tat activation. Using
r
a
i
r
1 n and
.this system, we found that eTat inhibited hTat activation
of elongation. We then used eTat as a competitive inhib-
itor to study the protein factors involved in the mecha-
nism of Tat activation.
This study resulted in several expected results and one
unexpected observation that led us to further characterize
the mechanism of eTat inhibition. We found that eTat spe-
cifically inhibits the hTat-dependent activation of elonga-
FIG. 5. Recovery of hTat transcription activity using P-TEFb-containing
ecovers hTat activity in reactions inhibited with eTat. Transcription elo
nd/or eTat and 4 ml of the indicated chromatographic fractions from
calculated for the experiment shown in panel A. (C) Cyclin T1, CDK9, a
ml) of the indicated chromatographic fractions from wild-type (WT) and
a membrane, and probed with antibodies against cyclinT1 (a-cyclinT1),
markers. NE, nuclear extract (30 mg). (D) Analysis of protein compositio
ndicated chromatographic fractions from wild-type and R43G mutant
elative positions of hcyclinT1 (87 kDa) and CDK9 (42 kDa) are indicat
5 kDa (indicated by arrows) specifically bound the wild-type eTat colum
eTat INHIBITIOtion. The explanation most consistent with previously pub-
lished data is that eTat inhibits hTat activation by competingwith hTat for binding to the cyclin T1 subunit of P-TEFb. The
eTat–cyclin T1 complex is incapable of recognizing the
HIV-1 TAR structure; therefore, eTat functionally sequesters
cyclin T1 (and associated factors). Our experiments also
permit us to conclude that hTat interacts with cyclin T1 in
the absence of TAR, the HIV-1 LTR, or ongoing transcription.
Moreover, our data support the contention that hTat, and
eTat, can form a stable complex with cyclin T1. These
ns. (A) Addition of chromatographic fractions from eTat affinity columns
reactions were performed in the absence (2) or presence (1) of hTat
type eTat affinity column. W, wash fraction. (B) Elongation efficiencies
SF1 are present in the active chromatographic fractions. Samples (20
(mt) affinity eTat columns were resolved by SDS–PAGE, transferred to
(a-CDK9), Tat-SF1 (a-Tat-SF1), and PCNA (a-PCNA). M, molecular size
e gradient fractions from eTat chromatography. Samples (10 ml) of the
eTat columns were resolved by SDS–PAGE and silver stained. The
eral unidentified proteins of apparent molecular masses 140, 32, and
roughly copurified with the activity capable of reversing eTat inhibition.
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data of others (Bieniasz et al., 1999; Garber et al., 1998;
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in vitro system permitted a direct evaluation of these phe-
nomena.
The unexpected observation from our experiments
came from attempts to reverse hTat-dependent activa-
tion from the inhibitory effect of eTat. It should be noted
again that the inhibition by eTat was very specific; only
hTat-activated elongation was inhibited. The elongation
efficiency of the HIV-1 LTR in the absence of exogenous
hTat was not affected by eTat, demonstrating that eTat
sequesters an activity specifically involved in Tat activa-
tion. Consistent with this, HTNE reversed the inhibition of
hTat-dependent activation of elongation but did not en-
hance basal elongation. Therefore, the HTNE provided
the activity that is specifically required for hTat activation
of elongation.
The most parsimonious hypothesis for these observa-
tions, when considering previously published data, is
that eTat inhibits hTat activity by sequestering P-TEFb. In
this case, the addition of purified P-TEFb (cyclin T1 and
CDK9) would be predicted to reverse eTat inhibition.
Purified recombinant P-TEFb, which was fully active in
enhancing elongation, gave a surprising result. rP-TEFb
overcame the eTat-mediated inhibition of hTat-activated
transcription elongation; however, rP-TEFb also in-
creased elongation efficiency of the HIV-1 in the absence
of hTat. This result suggests that the active form of
P-TEFb in HTNE is functionally distinct from rP-TEFb. The
most likely explanation is that the active component in
HTNE is a different form of P-TEFb complex, possibly
containing additional protein factors that modulate its
activity. The P-TEFb complex purified from wild-type eTat
affinity matrices support this hypothesis; P-TEFb copuri-
fied with Tat-SF1 and at least three other unknown fac-
tors from the wild-type eTat column. The identification of
these proteins will be an important step in characterizing
the form of P-TEFb that is bound by Tat and recruited to
RNAP II transcription complexes. Currently, little is
known about the identity of proteins that bind to or
associate with P-TEFb. However, several reports have
demonstrated that P-TEFb exists in protein complexes
with molecular weights greater than the minimal P-TEFb
complex (i.e., cyclin T1 and CDK9) (Parada and Roeder,
1999; Ramanathan et al., 1999; Goldstrohm et al., unpub-
ished data). In addition, several groups have begun to
haracterize P-TEFb-associated proteins (Kim et al.,
999; Parada and Roeder, 1999; Zhu et al., 1997). These
roteins may regulate the activity of P-TEFb and restrict
he spectrum of promoters affected by this positive elon-
ation factor.
MATERIALS AND METHODS
NA templates and recombinant proteins
364 SUNThe HIV-1 DNA templates WT and BL are the pBC12/
IV/SEAP plasmid (Berger et al., 1988) cut with SphI orBamHI to give runoff transcripts of 330 or 552 nucleo-
tides, respectively. The BL DNA template contains a
deletion of the TAR bulge region. The adenovirus type 2
major late (AdML) promoter template has been de-
scribed previously (Sune and Garcia-Blanco, 1995). The
HIV-1 double G-less cassette used in elongation assays
(Fig. 1C) is the pTZHIVdGless plasmid. The parental
pTZHIV was constructed by inserting a PCR fragment
containing HIV-1 LTR sequences (from 2460 to 159) into
pnI–BamHI-digested pTZ-18U plasmid (Pharmacia, Pis-
ataway, NJ). A PCR fragment encompassing a double
-less cassette was generated using pSLG402 as a
emplate(Lee and Greenleaf, 1997) and subcloned into
baI–SphI-digested pTZHIV to generate pTZHIVdGless.
he Adenovirus major late promoter double G-less tran-
cription template used was the plasmid pSLG402 de-
cribed by Lee and Greenleaf (1997).
Purification of biologically active hTat protein has been
escribed previously (Sune and Garcia-Blanco, 1995). To
xpress eTat proteins, sequences encoding wild-type
nd R43G mutant eTat gene products (Madore and
ullen, 1993) were subcloned into pGEX vectors (Phar-
acia) by standard techniques. Proteins were expressed
s glutathione-S-transferase fusions using the manufac-
urer’s protocols. Cleavage of the GST fusion proteins to
ield free eTat was carried out as described by Rhim et
l. (1993), except that 10 NIH units of human thrombin/ml
ere used. Integrity of proteins was analyzed by SDS–
AGE techniques and Western blotting with specific an-
isera.
Recombinant P-TEFb was produced using a baculovi-
us system as described by Peng et al. (1988). P-TEFb
as dialyzed in buffer D (20 mM HEPES, pH 7.9, 20% v/v
lycerol, 0.2 mM EDTA, 0.5 mM DTT, and 100 mM KCl) at
final concentration of 36 ng/ml.
Transcription reactions
The in vitro transcription system was performed as
previously described (Sune and Garcia-Blanco, 1995),
but 200 ng of each DNA was added to 25-ml transcription
reactions. HeLa nuclear extracts (15 mg/ml) were used
for all transcription assays (Dignam et al., 1983). Depend-
ing on the batch, 175–500 ng of recombinant hTat was
added to the transcription reactions. A sevenfold molar
excess of eTat to hTat was used in transcription reac-
tions, except where noted. Briefly, eTat and hTat proteins
were mixed and added to nuclear extract at 4°C; subse-
quently, DNA templates, ribonucleotides, and the other
components of the transcription reaction were added
from a master mix. Reactions were incubated at 30°C for
30 min, and RNA transcripts were isolated. The specific
bands were quantified by using a PhosphorImager (Mo-
lecular Dynamics Inc., Sunnyvale, CA). Specific trans-
AL.activation (Figs. 1B and 2B) was calculated as the ratio of
the level of the WT HIV-1 transcript in the presence of
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N OFhTat to the level of the same transcript in the absence of
hTat, normalized to the level of the BL control transcripts
in those reactions (Sune and Garcia-Blanco, 1995).
To generate HTNE, 250 ml of HeLa nuclear extract was
eated for 15 min at 47°C. This method inactivates TFIID
ctivity and thus renders the extract transcriptionly inac-
ive (Fig. 3C) (Nakajima et al., 1988; Sune and Garcia-
lanco, 1995).
Reactions used to analyze hTat-dependent transcrip-
ion elongation were incubated at 30°C for 45 min and
hen digested with 1000 U of RNase T1 (Ambion, Austin,
X) for 6 min at 37°C, followed by proteinase K (30 mg;
mbion) digestion for 15 min at the same temperature.
NA products were purified and analyzed as previously
escribed (Sune and Garcia-Blanco, 1995). The radioac-
ivity for each product was measured by a PhosphorIm-
ger and normalized for uridine content by dividing the
adioactivity of the product by the number of uridines in
he fragment (24 for the 85-nt cassette and 138 for the
77-nt cassette) (Lee and Greenleaf, 1997). Elongation
fficiency was then calculated as the molar ratio of long
o short transcripts. The trans-activation of long tran-
cripts was calculated by dividing the radioactivity mea-
ured for long transcripts in the presence of hTat by the
adioactivity of long transcripts in the absence of hTat.
he trans-activation of short transcripts was calculated
n a same way using the radioactivity measured for short
ranscripts.
ffinity chromatography
Wild-type and R43G mutant GST-eTat proteins were
ound to 0.5 ml of glutathione–agarose beads (Sigma
hemical Co., St. Louis, MO) and packed into disposable
oly-Prep chromatography columns (Bio-Rad Laborato-
ies, Hercules, CA). Approximately 3 mg of fusion protein
as immobilized in each column as determined by Brad-
ord assay (Bio-Rad) after elution of the fusion protein
rom a small aliquot of beads with free glutathione. In-
egrity of proteins was analyzed by SDS–PAGE. Proteins
ere bound covalently to the beads with dimethyl pime-
imidate (Pierce, Rockford, IL) as described by Koff et al.
1992). HeLa cell nuclear extract was prepared by the
ethod of Dignam et al. (1983) and adjusted to buffer D
20 mM HEPES, pH 7.9, 20% v/v glycerol, 0.2 mM EDTA,
.5 mM DTT, and 100 mM KCl). A total of 10 ml of nuclear
xtract (15 mg of protein/ml) was loaded onto each col-
mn at a flow rate of 0.1 ml/min, and the columns were
ashed with 60 bed volumes of buffer D containing
henylmethylsulfonyl fluoride (PMSF) at 50 mg/ml. Bound
roteins were eluted with 2 ml of a 0.1–1 M KCl gradient
n buffer D containing PMSF but without glycerol. Frac-
ions (0.3 ml) were collected, their protein concentration
eTat INHIBITIOnd conductance were measured, and selected fractions
ere dialyzed extensively against buffer D. These frac- Dions were used in transcription assays as described in
he legend for Fig. 5.
Analysis of the protein composition of the eTat column
ractions was carried out by SDS–PAGE and Western
lotting. Proteins were transferred to an Immobilon-P
Millipore Corp., Bedford, MA) membrane, which was
ncubated with the specific antisera. After washing, the
embrane was incubated with a peroxidase-conjugated
econdary antibody (Amersham, Arlington Heights, IL),
nd bound antibodies were detected by enhanced
hemiluminescence (Amersham). Rabbit polyclonal se-
um against cyclinT1 was provided by Katherine Jones
Wei et al., 1998). Antibodies against CDK9 and Tat-SF1
were obtained by immunizing rabbits with glutathione-
fusion proteins (Research Genetics Inc., Huntsville, AL).
Antibodies against proliferating cell nuclear antigen
(PCNA) were purchased from Santa Cruz Biotech (Santa
Cruz, CA).
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